<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04323098</url>
  </required_header>
  <id_info>
    <org_study_id>BMN 270-303</org_study_id>
    <secondary_id>2018-004616-21</secondary_id>
    <nct_id>NCT04323098</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A</brief_title>
  <acronym>GENEr8-3</acronym>
  <official_title>A Phase 3b, Single Arm, Open-Label Study to Evaluate the Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII, With Prophylactic Corticosteroids in Hemophilia A Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene&#xD;
      roxaparvovec in combination with prophylactic corticosteroids in patients with severe&#xD;
      hemophilia A.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in median FVIII activity as measured by chromogenic substrate assay, after administration of BMN 270 with prophylactic corticosteroids</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the annualized utilization (IU/kg) of exogenous FVIII replacement therapy or emicizumab for subjects receiving FVIII or emicizumab prophylaxis respectively after administration of BMN 270 with prophylactic corticosteroids</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the annualized number of bleeding episodes requiring exogenous FVIII replacement treatment after administration of BMN 270 with prophylactic corticosteroids</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of BMN 270 with prophylactic corticosteroids on quality of life as measured by the Haemo-QoL-A questionnaire</measure>
    <time_frame>52 weeks</time_frame>
    <description>Haemo-QoL-A is a hemophilia-specific, health-related quality of life questionnaire for adults, which uses a scale from 0 (none of the time) to 5 (All of the time) to report data.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>valoctocogene roxaparvovec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg with prophylactic corticosteroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>valoctocogene roxaparvovec</intervention_name>
    <description>Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A</description>
    <arm_group_label>valoctocogene roxaparvovec</arm_group_label>
    <other_name>BMN 270</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males ≥ 18 years of age with hemophilia A and residual FVIII levels ≤ 1 IU/dL as&#xD;
             evidenced by medical history, at the time of signing the informed consent.&#xD;
&#xD;
          2. Must have been on prophylactic hemophilia therapy for at least 12 months prior to&#xD;
             study entry.&#xD;
&#xD;
          3. Treated/exposed to FVIII concentrates or cryoprecipitate for a minimum of 150 exposure&#xD;
             days (EDs).&#xD;
&#xD;
          4. No previous documented history of a detectable FVIII inhibitor, &lt;0.6 Bethesda Units&#xD;
             (BU).&#xD;
&#xD;
          5. Sexually active participants must agree to use an acceptable method of effective&#xD;
             contraception. Participants must agree to contraception use for at least 12 weeks&#xD;
             post-infusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Detectable pre-existing antibodies to the AAV5 capsid. Up to 25% of subjects may have&#xD;
             detectable pre-existing AAV5 capsid antibodies, so long as the titer level is below&#xD;
             the minimum required dilution (&lt; 20).&#xD;
&#xD;
          2. Any evidence of active infection or any immunosuppressive disorder; patients with HIV&#xD;
             infection and undetectable viral load are not excluded.&#xD;
&#xD;
          3. Significant renal dysfunction or liver dysfunction, infection or history of hepatic&#xD;
             malignancy.&#xD;
&#xD;
          4. Evidence of any bleeding disorder not related to hemophilia A.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Biological males only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioMarin Pharmaceutical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Specialist</last_name>
    <phone>1-800-983-4587</phone>
    <email>medinfo@bmrn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Campinas University Clinical Hospital</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Medical Foundation Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gene Therapy</keyword>
  <keyword>Clotting Disorders</keyword>
  <keyword>Blood Disorder</keyword>
  <keyword>Blood Coagulation Disorders</keyword>
  <keyword>Inherited Blood Coagulation Disorders</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Coagulation Protein Disorders</keyword>
  <keyword>Hemorrhagic Disorders</keyword>
  <keyword>Genetic Diseases</keyword>
  <keyword>Factor VIII</keyword>
  <keyword>Coagulants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

